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Agomelatine is an antidepressant with a unique mechanism of action. Since its marketing in 2009, concerns
have been raised regarding its potential to induce liver injury. The authors therefore address the need to
comprehensively evaluate the potential risk posed by agomelatine of inducing liver injury by reviewing data from
published and unpublished clinical trials in both the pre- and postmarketing settings, as well as data from
non-interventional studies, pharmacovigilance database reviews and one case report. Recommendations for
clinicians are also provided.
In this review, agomelatine was found to be associated with higher rates of liver injury than both placebo and
the four active comparator antidepressants used in the clinical trials for agomelatine, with rates as high as 4.6%
for agomelatine compared to 2.1% for placebo, 1.4% for escitalopram, 0.6% for paroxetine, 0.4% for fluoxetine,
and 0% for sertraline. The review also provides evidence for the existence of a positive relationship between
agomelatine dose and liver injury. Furthermore, rates of liver injury were found to be lower in non-interventional
studies. Findings from pharmacovigilance database reviews and one case report also highlight the risk of
agomelatine-induced liver injury.
As agomelatine does pose a risk of liver injury, clinicians must carefully monitor liver function throughout
treatment. However, agomelatine’s unique mechanism of action and favourable safety profile render it a valuable
treatment option.
A quantitative analysis of agomelatine-induced liver injury is lacking in the literature and would be welcomed.
Keywords: Adverse event, Antidepressant, Clinical recommendations, Depression, Hepatotoxicity,
Melatonin analogueIntroduction
Synthesized for the first time in 1992 [1], agomelatine
has been licensed for the treatment of Major Depressive
Disorder (MDD) in adults since 2009 in the European
Union [2] and since 2010 in Australia [3].
Its short-term efficacy and tolerability have recently
been systematically examined by Taylor et al. [4] using
data from both published and unpublished clinical trials.
In short, agomelatine was found to be more effective
than placebo, and no more or less effective than other
antidepressants (AD) in reducing acute symptoms of de-
pression. Agomelatine was furthermore not found to be
more effective than placebo or other ADs in achieving
remission from depression. In a similar systematic* Correspondence: karolina.furczyk@med.uni-rostock.de
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article, unless otherwise stated.review by Guaiana and colleagues [5] comparing agome-
latine solely to other ADs, agomelatine was found to be
as effective as other ADs in reducing acute symptoms of
depression and in achieving remission.
Prior to, and after the marketing of agomelatine, con-
cerns have been raised regarding its potential to induce
liver injury, where liver injury, or hepatotoxicity, can be
defined as injury to the liver that is associated with clin-
ically significant elevations in liver serum transaminase
titers of >3X upper limit of normal (ULN; [6,7]). Indeed,
findings from premarketing trials have been pooled and
list increases in liver serum transaminase titers of >3X
ULN as a common side effect (seen in one in every 10-
100 patient) [2,8]. Cases of serious hepatic reactions
such as cytolytic hepatitis have also been reported to
have occurred at a rate of one in every 1000-10 000 per-
sons, rendering such occurrences as rare side-effectsBioMed Central. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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occurred, with no exact data available [8]. Since its mar-
keting, cases of serious hepatic reactions including
hepatitis and jaundice, as well as liver enzyme elevations
of >10X ULN have been reported to occur at a rate of one
in every 1000-10 000 persons, rendering these occurrences
as rare side effects [2,9]. To date, there have been six
reported cases worldwide of hepatic failure resulting in
death or liver transplantation in people with hepatic
risk factors [10]. The manufacturer of agomelatine has
responded to these concerns by emitting safety informa-
tion letters and liver monitoring guidance protocols for
the healthcare professionals prescribing agomelatine, the
latest update being released in October 2013 [10].
As all ADs have the potential to induce liver injury
even at therapeutic doses [7], and the most common
reason for a drug to be rejected for application or with-
drawn from the market in the United States being drug-
induced liver injury (DILI; [11]), with similar guidelines
applied by the European Medicines Agency [12], there is
a need to critically evaluate and review the risk of DILI
following the administration of agomelatine in the treat-
ment of MDD in adults. Therefore, the following article
will review the risk posed by agomelatine of inducing
liver injury, and will attempt to determine if its benefits
outweigh its’ risk of hepatotoxicity.
Literature search
A PubMed search of full-text articles written in the
English language using the search terms “agomelatine”,
“agomelatine hepatotoxicity”, and “agomelatine liver”
was conducted. Clinical trials, non-interventional stud-
ies, pharmacovigilance database reviews and case reports
were identified. A total of 15 clinical trials were selected
as blood samples or liver function tests were performed
as part of their study design and as the results of these
tests were reported. In addition, the unpublished data
from the premarketing clinical trials of agomelatine with
available results were reviewed from the European Medi-
cines Agency [8] and the Novartis Clinical Trial Results
Database [13]. We additionally consulted the ADFD
Wissen website to obtain a complete list of all clinical
trials sponsored by Servier® [14]. This generated a total
of six additional articles that were selected. Three non-
interventional studies, two pharmacovigilance database
reviews and one case report were furthermore selected
using these search terms.
To help contextualize our review, review articles with
full-text availability were searched using the search terms
“agomelatine liver” and “agomelatine hepatotoxicity”. This
generated a total of 14 articles, of which two were selected
for their relevance. Likewise, to obtain information on the
AD efficacy of agomelatine, a search of systematic reviews
with full-text availability was conducted using the terms“agomelatine antidepressant efficacy”. A total of 15 articles
were generated, with five articles being selected for their
relevance. Of these five review articles, we also consulted
all relevant articles in their reference lists.
Lastly, Servier Laboratories were contacted to obtain
additional unpublished data.
As no experimental research was conducted to create
this review, no ethical approval has been applied for.
Pharmacology of agomelatine
Mechanism of action
Circadian abnormalities are a central symptom in MDD
pathology [15] (Li et al., 2013). In this sense, agomelatine
is a unique ADs as it is a melatonin analogue that acts
both as a melatonin-receptor agonist at MT1 and MT2
receptors [16] and a selective serotonin-receptor antag-
onist at 5-HT2C receptors [17]. This unique mechanism
of action confers agomelatine with the ability to regulate
disrupted circadian rhythms by specifically: (1) inducing
a phase advance of sleep, (2) reducing core body
temperature, and by (3) positively phase shifting mela-
tonin onset [2]. In an open-label EEG study with MDD
patients, agomelatine has further been shown to increase
slow-wave sleep duration and sleep efficiency [18].
Moreover, its antagonistic effects at 5-HT2C receptors
result in an increased extracellular release of noradren-
aline and dopamine in the frontal cortex [17], endowing
agomelatine with a more conventional AD profile as it
affects mood control. Lastly, agomelatine has further
been shown to have anxiolytic properties [19].
Absorption and distribution
Agomelatine is rapidly and almost completely absorbed
after oral ingestion. After administration of 25-50 mg,
maximum blood concentration is achieved between 45
and 90 minutes [8], and is absorbed at a rate of ≥ 80%.
Intra- and inter-individual variability in bioavailability
is considerable, and has been estimated to be higher in
women compared to men, and higher in elderly com-
pared to younger individuals. Therefore, sex and age
are factors that have been suggested to affect the meta-
bolic enzyme activity of agomelatine and hepatic blood
flow [8].
Metabolism and biotransformation
90% of agomelatine is metabolised through the liver by
the hepatic cytochrome P450 1A2 (CYP1A2), and 10% by
cytochromes CYP2C9 and CYP2C19 [3], where it under-
goes high first-pass hepatic metabolism. Agomelatine has
at least four main metabolites, none of which have shown
any toxic effects. Up to 80% of agomelatine is eliminated
in urine as pharmacologically inactive metabolites, the
main metabolites being hydroxylated and demethylated
agomelatine [2,3].
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According to Gahr and colleagues [20], the mechanism
underlying the agomelatine-induced liver injury appears
to be idiosyncratic. This type of reactions occurre in most
instances 5-90 days after the causative medication was last
taken [21]. The mechanism of injury can be hepato-
cellular (predominant rise in alanine aminotransferase
[ALT]), cholestatic (predominant rise in alkaline phos-
phatase [ALP]) or mixed [21].
Review
Adverse drug reactions: liver injury and agomelatine
Findings from the pre- and postmarketing clinical trials
and non-interventional studies reporting agomelatine-
induced liver injury are synthesized in Table 1.
Premarketing studies
European clinical trials A pooled analysis of all com-
pleted Phase II/III European clinical trials of all indica-
tions (i.e., Overall Safety Set) was completed by the
European Medicines Agency [8]. The analysis included a
total of 4068 patients who received agomelatine, but it is
not clear how many patients who received placebo were
included. Significant elevations (>3X ULN) in alanine ami-
notransferase (ALT) and/or asparate aminotransferase
(AST) liver enzymes in patients with normal values at
baseline were reported at a rate of one in every 10-100 pa-
tients, rendering this finding a common occurrence. Spe-
cifically, significant elevations in liver enzymes occurred in
1.04% of patients taking 25 mg agomelatine, 1.39% taking
50 mg, and 0.72% taking placebo. All liver reactions ob-
served were hepatocellular and occurred early during the
six-month treatment period. Most reactions recovered
within a few weeks, while others recovered during contin-
ued treatment or upon treatment discontinuation. Hepatic
reactions occurring after three or six months of treatment
were also observed, with no exact data given. Further-
more, rare cases of serious hepatic reactions (e.g., cytolytic
hepatitis) have also been reported to have occurred at a
rate of one in every 1000-10 000 persons [2,8]. Liver en-
zyme elevations of >10X ULN have also occurred, with no
exact data available [8].
Short-term, multicenter, USA clinical trials In an
eight-week phase III clinical trial study by Zajecka and
colleagues [22,23], no significant elevations in liver
enzymes occurred in patients receiving either 25 mg
agomelatine or placebo, but did occur in seven patients
(4.5%) receiving 50 mg agomelatine. All liver reactions
occurred within the sixth and eighth weeks of treatment.
One patient discontinued treatment and their liver
function tests normalized, and the other six patients
continued treatment and their liver function tests nor-
malized. The authors indicate that baseline hepatobiliarydisorders (mainly in the form of cholecystitis, gallbladder
disorder, and hepatic steatosis) existed in 3.1% of pa-
tients taking 50 mg agomelatine, in 0.6% taking 25 mg,
and 0.6% receiving placebo. However, the authors do not
indicate whether the existence of hepatobiliary disorders
was associated with the significant increases in liver en-
zymes observed.
In a second eight-week clinical trial study by Stahl and col-
leagues [24,25], significant elevations in liver enzymes were
noted in one patient (0.6%) taking 25 mg agomelatine, in
five patients (3.0%) taking 50 mg agomelatine, and in one
patient (0.6%) taking placebo. Again, most liver reactions
occurred within the sixth and eighth weeks of treatment.
Two agomelatine (50 mg) patients discontinued treatment
and their liver function tests normalized, and four patients
continued treatment during a one-year extension phase
and their liver function tests normalized. One agomelatine
patient (25 mg) was lost to follow-up.
In an unpublished eight-week phase III clinical trial
[26], significant elevations in liver enzymes were found
to occur in three patients (1.9%) taking agomelatine (two
patients taking 25 mg agomelatine, and one patient tak-
ing 50 mg agomelatine), and in one patient (0.6%) taking
20 mg paroxetine. No patient receiving placebo devel-
oped clinically notable elevations in liver enzymes. One
agomelatine (25 mg) patient discontinued treatment and
their liver function tests normalized one day after dis-
continuation. It is mentioned that this patient had
consumed alcohol the day before elevated liver en-
zymes were reported. The two other agomelatine pa-
tients continued treatment and their liver functions
tests normalized. The patient receiving paroxetine
continued treatment with agomelatine in an open-
label extension phase and their liver function tests
normalized.
Short-term multinational clinical trials Hale et al. [27]
compared agomelatine (25/50 mg) to fluoxetine (20/40
mg) during eight-weeks in outpatients diagnosed with
MDD. Significant liver enzyme elevations were noted in
four patients (1.6%) receiving agomelatine and in one pa-
tient (0.4%) receiving fluoxetine (percentages calculated
using the safety set; i.e. all enrolled patients who received
at least one dose of the study treatment). It is not indicated
whether patients received 25 mg or 50 mg agomelatine.
All patients continued treatment and their liver enzyme
values normalized, in one case during the study treatment.
In a six-week study by Kasper et al. [28], where pa-
tients with MDD received either agomelatine (25/50 mg)
or sertraline (50/100 mg), significant elevations in liver
enzymes were noted in one patient (0.7%) receiving ago-
melatine (dosage not mentioned; percentage calculated
using the safety set). The authors describe this patient as
an alcoholic, and no additional information is provided.
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deaths due to hepatic reaction
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Hale et al. (2010) [27] 515 8 MDD Ago25/50: 1.6%5
Flx20/40: 0.4%
0%





329 52 MDD Ago25/50: 2.0% 0%
CAGO178A2302E1
(2009) [30]
358 52 MDD Ago25/50: 2.0% 0%
CAGO178A2303E1
(2010) [31]
334 52 MDD Ago25: 1.2%6
Ago50: 2.0%6
0%





Calabrese et al. (2007) [33] 21 6, plus optional
46 (total 52)
bipolar I disorder Ago25: N/A 0%
Olié & Kasper (2007) [34] 238 6 MDD Ago25/50 and Pbo: N/A 0%
Goodwin et al. (2009) [35] 339 34 MDD Ago25/50 and Pbo: N/A 0%
Demyttenaere et al.
(2013) [36]




Bruno et al. (2013) [37] 15 12 Fibromyalgia Ago25: 0% 0%
Martinotti et al. (2012) [38] 60 8 MDD Ago25/50 and Vlx75/150: N/A 0%
Stein et al. (2012) [39] 477 43 GAD N/A 0%
Stein et al. (2014) [40] 412 12 GAD N/A 0%
Heun et al. (2013) [41] 222 8 MDD Ago25/50: 1.3%5
Pbo: 0%
0%
Laux and the VIVALDI
Study Group (2012) [42]
3356 12 MDD Ago25/50: 0.2%8 0%
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138 24 MDD Ago25/50 and
Esci10/20: N/A
0%
Montejo et al. (2010) [46] 92 8 healthy volunteers Ago25/50, Par20,
and Pbo: N/A
0%
Ago25 = 25 mg agomelatine; Ago50 = 50 mg agomelatine; Ago25/50 = entire agomelatine treatment group; Pbo = placebo; Par20 = 20 mg paroxetine,
Flx20/40 = entire fluoxetine treatment group; Ser50/100 = entire sertraline treatment group; Vlx75/150 = entire venlafaxine treatment group; Esci10/20 = entire
escitalopram treatment group; SSRIs: selective serotonin reuptake inhibitors; MDD = Major Depressive Disorder; GAD = Generalized Anxiety Disorder; Slp = sleep;
N/A = non-vailable.
1: Number of patients receiving agomelatine; the number of patients receiving placebo is not clear.
2: Classified as a common event.
3: Classified as a rare event.
4: Case did not recover at follow-up (2.5 years after end of study).
5: Percentage calculated from safety set (i.e., enrolled patients who received at least one dose of the study treatment).
6: Percentage calculated from all treated patients enrolled in the extension phase.
7: Percentages calculated from information provided in Novartis Clinical Trial Results Database, 2010—study CAGO178A2.
304.
8: It is not mentioned by the authors if other ADs were taken concurrently.
9: Percentage calculated from information provided in the article.
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published 52-week, open-label extension phase study
[29] to the published study by Zajecka et al. [22], six pa-
tients (2.0%) showed significant liver enzyme elevations.
Specifically, three patients showed significant elevations
in ALT values. All significant values normalized; two pa-
tients discontinued treatment and one patient recovered
while on treatment. The other three patients showed sig-
nificant elevations in gamma-glutamyl transferase (GGT)
values. No additional information is provided concerning
these patients. Lastly, one death occurred, with liver in-
jury not being the cause of death [H. Maul, personal
communication].
In a similar 52-week, open-label extension phase study
to the published study by Stahl et al. [24,30], seven pa-
tients (2.0%) developed significant liver enzyme eleva-
tions. Of these patients, it is only mentioned that three
recovered (two after treatment discontinuation and one
while on treatment). No information regarding the other
four patients is provided. Again, one death occurred,
with liver injury not being the cause of death [H. Maul,
personal communication].
Lastly, in another unpublished 52-week, open-label exten-
sion phase study to the study numbered CAGO178A2303
[26,31], one patient taking 25 mg agomelatine and five pa-
tients taking 50 mg agomelatine developed significantly el-
evated liver enzymes. Based on all treated patients in the
extension phase, this would equal to 1.2% taking 25 mg
agomelatine and to 2.0% taking 50 mg agomelatine. No
additional information is provided. No deaths occurred
during the extension phase.
Relapse prevention studies Data from a 52-week, ran-
domized, double-blind, placebo-controlled, relapse pre-
vention study is also available [32]. Following an initial
16-24 weeks of open-label treatment with agomelatine
(25/50 mg), 29 patients (4.6%; specific dosage notreported) developed liver enzyme elevations. During the
double-blind treatment phase, three patients (2.1%) re-
ceiving placebo developed liver enzyme elevations). In
neither treatment phase is it mentioned whether these
elevations were significant. However, according to add-
itional information received from Servier Labolatories,
the reported elevations were not significant [H. Maul,
personal communication].
Other studies The following three studies were in-
cluded, as blood samples were taken as part of the over-
all safety measures, and as the results from these blood
samples are reported. However, it is not clear whether
liver function tests were specifically performed.
Calabrese et al. [33] tested the AD efficacy of 25 mg ago-
melatine in patients with bipolar I disorder in an initial
six-week open-label treatment phase followed by an op-
tional extension phase up to 46 weeks (52 weeks total).
The authors note that the results of all biochemical and
blood parameters were not clinically relevant.
Olié and Kasper [34] compared agomelatine (25/50 mg)
to placebo in an international, prospective, randomized,
double-blind, parallel-group study in MDD patients. Re-
sults of the biochemical variables examined are not specif-
ically reported by the authors, but they do mention that
no relevant differences between treatment groups were
observed in any of the biochemical variables examined
during treatment. The authors further mention that the
most common reason for study discontinuation was lack
of treatment efficacy. Taken together, this information
likely suggests that significantly elevated liver enzymes
were not observed during the study period.
In a multinational, randomized, double-blind, placebo-
controlled, relapse prevention study by Goodwin et al.
[35] MDD patients who responded to an initial eight or
ten-week agomelatine treatment period received either
agomelatine (25/50 mg) or placebo for an additional 24
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served from baseline to the end of the treatment in any of
the haematological and biochemical variables examined.
Postmarketing studies
In an update from the Medicines and Healthcare products
Regulatory Agency in 2012 [9], it is mentioned that six re-
ported cases worldwide of hepatic failure [rate of one in
every 1000-10 000 persons; 10] have occurred since Ser-
vier was granted marketing authorization of agomelatine
in 2009, resulting in death or liver transplantation in
people with hepatic risk factors. Serious hepatic reactions
including hepatitis (cytolytic) and jaundice, and elevations
of liver enzymes >10X ULN have also been reported, with
no exact frequency data given [10]. It is mentioned how-
ever that most reactions occurred during the first months
of treatment, were hepatocellular, and that liver enzymes
usually normalized upon treatment cessation. Only one
case of hepatitis did not recover at follow-up after discon-
tinuation of agomelatine (2.5 years after the end of the
study) is reported.
Data from clinical trials examining the long-term
safety of agomelatine compared to other ADs have also
recently become available via the publication of a meta-
analysis by Demyttenaere et al. [36]. In their analysis of
four clinical trials with an extension phase of up to 24
weeks, the authors note that significant elevations in
liver serum transaminase values occurred in eight patients
(1.75%) receiving 25 mg agomelatine, in four patients
(2.61%) receiving 50 mg agomelatine and in two patients
(0.34%) receiving a comparative AD (either fluoxetine,
sertraline or escitalopram) during the extension phase.
These results are similar to those reported in short-term
clinical trials and in the pooled analysis of all completed
Phase II/III European clinical trials by the European Medi-
cines Agency (European Medicines Agency [8].
European clinical trials Bruno et al. [37] examined the
efficacy and tolerability of agomelatine (25 mg) in the
treatment of fibromyalgia in a twelve-week, open-label
study. Liver function tests were measured at inclusion
and upon completion of the study. Twelve females com-
pleted the study, and none showed significant changes in
any of the laboratory parameters examined.
In an eight-week, open-label pilot study by Martinotti
et al. [38] comparing agomelatine (25/50 mg) and venlafax-
ine (75/150 mg) in the treatment of anhedonia in MDD,
liver enzyme values were examined at baseline and at the
end of the study. The authors report that no clinically rele-
vant differences were seen between treatment groups in the
mean change from baseline in liver enzyme values.
Multinational trials In a six-month, randomized, double-
blind, placebo-controlled study in patients with GeneralizedAnxiety Disorder (GAD) by Stein et al. [39], it is mentioned
that potentially clinically significant abnormal liver enzyme
values were noted in 17 patients (3.6%). Specifically, ten pa-
tients received 25 mg agomelatine, 3 patients received 50
mg agomelatine, and 5 patients received placebo; one pa-
tient receiving 25 mg agomelatine continued to show ele-
vated liver enzyme values when switched to placebo in the
maintenance period of the study. Here, it is not possible to
calculate percentages per group (i.e., agomelatine 25, ago-
melatine 50, and placebo), as information regarding total
group numbers is lacking. The authors additionally men-
tion that all abnormal values normalized during the treat-
ment period, except for total bilirubin values in three
patients receiving placebo. No patient receiving agomela-
tine terminated treatment due to adverse events, whereas
two patients receiving placebo did during the maintenance
period. It is not clear whether this was specifically due to
significant liver enzyme elevations.
In a similar study by Stein et al. [40] in outpatients
diagnosed with GAD who received agomelatine (25/50
mg), escitalopram (10/20 mg) or placebo, two patients
(1.4%) receiving agomelatine and two patients (1.4%) re-
ceiving escitalopram showed significant elevations in
liver enzymes (percentages calculated from safety set).
The dosage these patients received is not indicated. No
patient in the placebo group showed significant liver en-
zyme elevations. No patient discontinued the study due
to significantly elevated liver enzymes, and the authors
mention that all liver function tests normalized upon
treatment discontinuation.
In an eight-week study in elderly MDD outpatients
(aged ≥ 65 years) comparing agomelatine (25/50 mg) to
placebo by Heun et al. [41], two patients (1.3%; percent-
age calculated from safety set) receiving agomelatine
(one aged ≥ 75 years; specific dosage not reported) with
normal liver enzyme values at baseline showed signifi-
cant elevations in liver enzymes during the study treat-
ment. The authors mention that these reactions were
likely due to agomelatine and that all abnormal values
normalized upon treatment discontinuation.
Non-interventional studies in routine practice In a
12-week study of patients by Laux and the VIVALDI Study
Group 2 [42], significant elevations in liver enzymes spe-
cifically reported as an adverse drug reaction were noted
in eight patients (0.2%). For five patients, it was possible
for the authors to assess the evolution of abnormal liver
enzyme values as both baseline and at least one follow-up
value were available. In short, two patients (0.1%) were
found to have normal ALT values at baseline that signifi-
cantly increased during the study period, and two patients
(percentage not provided) had elevated, but not signifi-
cantly elevated ALT values (i.e., >ULN and ≤ 3X ULN) at
baseline that reached significant levels during the study
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at baseline that also significantly increased during the
study. Finally, one patient (percentage not provided)
showed significant AST elevations, but no significant ALT
elevations during the observation period. For all informa-
tion regarding significant liver enzymes, it is not clear
whether patients received 25 mg or 50 mg agomelatine,
and whether patients received other concurrent medica-
tion(s). It is also not specified when these liver reactions
occurred during treatment, whether any of these patients
discontinued treatment, and whether liver function tests
normalized upon treatment cessation.
Sparshatt and colleagues [43] also conducted a 12-
week non-interventional study with difficult-to-treat or
refractory MDD patients. At baseline (99.1% taking 25
mg agomelatine), liver enzyme values for three patients
(3.6%) were outside the normal reference range, but all
were within 3XULN range, and one patient’s (0.9%; per-
centages calculated from information provided in the
article) liver enzyme values were significantly elevated.
This patient discontinued treatment, with the prescriber
stating “liver disorder” as the reason for treatment dis-
continuation. However, as the abnormal liver enzyme
values were noted at baseline, it is unlikely that agomela-
tine treatment resulted in the observed finding. At week
eight, results from 13 patients (14.9%) were outside the
normal reference range, but none were significantly ele-
vated. Of these patients, ten continued treatment (of
whom two had abnormal values at baseline) and three
discontinued treatment due to a lack of efficacy. It
should be noted that 23 patients (20.1%) received at least
one additional AD in addition to agomelatine at base-
line. Thus, establishing causality between drug treatment
and hepatotoxicity is rendered more complex. Lastly, it
is mentioned that liver function tests were performed at
week 12, but the results from these tests are not
provided.
Karaiskos et al. [44] compared agomelatine (25/50 mg)
and sertraline (50/200 mg) for the treatment of depression
in type II diabetes. Liver function tests were performed at
baseline and after six weeks of treatment. The authors
mention that both treatments were well tolerated, and that
no patient dropped-out of the study. No further details
are provided.
Other studies As in section 1.6, the following two stud-
ies were included as blood samples were taken as part of
the overall safety measures, and as the results from these
blood samples are reported. However, it is likewise not
clear if liver function tests were specifically performed.
In a 24-week multinational, multicentre sleep study
by Quera-Slava et al. [45], agomelatine (25/50 mg) and
escitalopram (10/20 mg) were compared in terms of AD
efficacy, as well as regarding their effects on nighttimesleep and daytime condition. Measures of haematology
and biochemistry were tested at baseline, and at weeks
six and twelve. No clinically relevant findings were
observed.
In an eight-week study comparing the effects of ago-
melatine (25/50 mg), paroxetine (20 mg) and placebo on
measures of sexual acceptability in healthy male subjects
by Montejo et al. [46], the authors report that no clinic-
ally relevant changes in mean values of biochemical and
blood parameters were observed.
Case report We found one published case report of
agomelatine-induced liver injury [47]. After 3 weeks of
agomelatine treatment (dose increased from 25 mg to
50 mg in one week; no concurrent medications listed), a
female patient aged 44 years old showed significant ele-
vations in liver enzyme. The author indicates that the
patient did not have a history of liver disease and that
their liver function tests at baseline were within the nor-
mal range. The type of liver damage observed was hepa-
tocellular, and the patient’s liver enzyme values returned
to normal upon agomelatine discontinuation.
Pharmacovigilance database reviews Gahr et al. [20]
analysed reports of agomelatine-related liver injury
submitted to a German pharmacovigilance database. 58
cases were submitted, most of which (79%) being asymp-
tomatic increases in liver enzymes. Six cases (10%) of
agomelatine-related hepatitis were also found. In their
analysis, the authors mention that the female gender, in-
creased age (mean 48.5 years; range 39-58), and poly-
pharmacy may be risk factors for agomelatine-related
hepatotoxicity.
Likewise, Montastruc and colleagues [48] analysed
the overall prevalence of agomelatine-related liver in-
jury, compared to that of 17 other ADs using data from
Spanish, French, Italian, and Portuguese pharmacovigilance
databases. In total, 3300 cases of AD-related liver injury
were reported and collected from the databases surveyed,
accounting for 10.3% of all cases collected for these drugs.
The authors further report that a total of 63 cases of
agomelatine-related liver injury were found since its market
introduction until the end of the study period, accounting
for 14.6% of AD-related liver injury compared to the other
ADs included in their review. Agomelatine was further
found to be statistically associated with liver injury in Spain,
France and Italy. As mentioned by the authors, the different
prevalence rates found for all drugs combined in compari-
son to agomelatine might be explained by different guide-
lines regarding the reporting of adverse drug events for
different drugs to pharmacovigilance databases. Another
explanation provided by the authors concerns differences
in the prescription of ADs in terms of patient population
and duration.
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Dose-effect relationship
Findings supporting the claim that increased drug dos-
age increases the risk of DILI have been observed in the
premarketing trials of agomelatine. Based on this review,
it is harder to establish such a relationship in the post-
marketing setting as results from most studies are re-
ported for the entire agomelatine group (i.e., 25/50 mg
combined). However, one could hypothesize the exist-
ence of such a relationship (see [49]).
Time of treatment
It is not clear whether and if so, to what extent, a risk
of liver injury under agomelatine treatment changes in
time. Various studies presented here report the signifi-
cant increase of liver enzymes occurs most often in the
first weeks of treatment. As already mentioned, the
idiosyncratic reactions, which are currently assumed to
underly the agomelatine-induced liver injury, most
often occur in 5-90 days after the last administration of
the causative medication [21]. The various currently
available reports on the prevalence of side effects in-
cluding agomelatine-related liver injury cover a pre-
defined treatment period of 6 to 52 weeks (compare
Table 1). However, our search did not provide any trials
looking at the risk of liver injury in patients treated
with agomelatine over a time period longer than one
year. Taking into consideration the fact that antidepres-
sant medication is usually given as a chronic or long-
time treatment, conducting long-time observations
(over 2 and more years preferably) would provide key
information with regard to the long-time drug safety
and undoubtedly be welcomed by clinicians.
Special populations
Impaired liver function No data from patients with
hepatic insufficiency (i.e., cirrhosis or other active liver
diseases) are available in Phase II/III studies as this clin-
ical condition was an exclusion criterion [8]. However,
an open-study (PKH-014) was performed to evaluate the
influence of hepatic insufficiency in patients with mild
(Child-Pugh grade A) or moderate (Child-Pugh grade B)
liver failure due to alcohol cirrhosis after taking a single
dose of 25 mg agomelatine [8]. On average, the increase
in agomelatine exposure was 70-fold higher in patients
with mild liver insufficiency compared to healthy con-
trols, and 140-fold higher in patients with moderate liver
insufficiency compared to healthy controls. Thus, liver
insufficiency leads to a significant increase in agomela-
tine exposure, and therefore agomelatine is contraindi-
cated in patients with a hepatic insufficiency.
Elderly and youth As agomelatine has not been found
to be effective in elderly patients (≥75 years) diagnosedwith MDD, it should not be prescribed to patients in this
age group [8]. However, findings from Heun et al. [41]
highlight the need to further evaluate the efficacy of ago-
melatine in MDD patients aged ≥65 years, as agomela-
tine was found to be effective in this age group—
although no real value was found in a subgroup of pa-
tients aged ≥75. Also, as mentioned previously, Heun
et al. [41] did note significant liver enzyme elevations in
two patients during their 8-week study (one patient aged
≥75 years). More data would thus be welcomed to add-
itionally gain a better understanding of agomelatine-
related liver injury in this age group.
In addition, agomelatine is not recommended for chil-
dren and adolescents under the age of 18 suffering of
MDD as no clinical trials were conducted in this popula-
tion [8].
Drug-drug interactions
In a study investigating the combined administration of
fluvoxamine (a potent CYP1A2 inhibitor) and agomelatine,
a 60-fold increase in the drug concentration over time (or
AUC, for area under the curve) was shown [8]. Indeed,
fluvoxamine inhibits the metabolism of agomelatine, result-
ing in an increased exposure to agomelatine. Therefore, the
concomitant administration of agomelatine with potent
CYP1A2 inhibitors (e.g., fluvoxamine or ciprofloxacin) is
contraindicated. Caution is furthermore recommended
when prescribing agomelatine with moderate CYP1A2 in-
hibitors (e.g., propanolol, grepafloxacin, and enoxacin).
Findings from Gahr and colleagues [20] likewise highlight
polypharmacy as a potential risk factor for agomelatine-
induced hepatotoxicity.
Discussion
To our knowledge, this is the first review that solely
provides an in-depth evaluation of agomelatine-induced
liver injury compared to placebo and the four active
comparator AD treatments used in the clinical trials for
agomelatine by reviewing findings from both the pre-
and postmarketing settings, and by including published
and unpublished studies. Findings of agomelatine-
induced liver injury from non-interventional studies, phar-
macovigilance database reviews and one case report are
also reported.
When combining findings from pre- and postmarket-
ing clinical trials, we find that significant elevations in
liver enzymes (>3X ULN) have been found to occur at a
rate of up to 4.6% (25/50 mg) following the administra-
tion of agomelatine (see study CAGO178A2304; [33]).
This is in-line with the information found in the Sum-
mary of Product Characteristics for agomelatine, where
significant liver enzyme elevations are noted to have oc-
curred at a rate of one in every 10-100 patients during
the clinical trials of agomelatine [2]. Findings from the
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cate that the risk of agomelatine-induced liver injury in-
creases with increasing dosage, where 1.04% of patients
treated with 25 mg/day reported significantly elevated
liver enzyme values compared to 2.5% of patients treated
with 50 mg/day and 0.6% receiving placebo [8,50].
However, we have also seen that receiving a placebo as
well as any of the four active comparator ADs selected
in the clinical trials for agomelatine poses a risk of indu-
cing liver injury at similar rates—but on average less—
compared to agomelatine. Indeed, rates of liver injury
were found to have occured at a rate as high as 2.1% for
placebo, 1.4% for escitalopram, 0.6% for paroxetine, 0.4%
for fluoxetine, and 0% for sertraline. Although not com-
pared in this review, it is worth noting that Voican et al.
[7] recently highlighted the increased risk of liver injury
following the administration of several commonly pre-
scribed AD treatments, with rates higher or very similar
to those of agomelatine. To name a few, the authors list
the ADs iproniazid, nefazodone, phenelzine, imipramine,
and amitriptyline (for a complete list, see [7]). Likewise,
the available AD duloxetine has recently come under scru-
tiny after 13 cases of death due to hepatic failure being re-
ported [51]. The same review by Voican et al. [7] showed
citalopram, escitalopram, paroxetine, and fluvoxamine
seem to have the least potential for hepatotoxicity. At any
rate, it is important to note that elevated, yet not clinically
significant elevations in liver serum transaminase titers
(i.e., <3X ULN) have been found to occur at a rate of ap-
proximately 1% to 5% within the general population [52].
Furthermore, liver enzyme values of <3X ULN have been
noted to be observable in approximately 20% of individ-
uals receiving placebo during phase 1 clinical trials [53].
Therefore, results showing clinically significant liver en-
zyme elevations from patients receiving AD-treatment
should be interpreted with caution, as a baseline variability
in liver enzyme values is observable in the general
population.
Interestingly, we found a lower incidence rate of signifi-
cantly elevated liver enzymes following the administration
of agomelatine in non-interventional studies. Specifically,
Laux and the VIVALDI Study Group [42] report a rate of
0.2% and Sparshatt et al. [43] report a baseline rate of
0.9%. However, as previously mentioned, it is unlikely that
the administration of agomelatine caused the significantly
elevated liver enzyme values observed in the study by
Sparshatt et al. [43], as the abnormal values were reported
at baseline. One hypothesis to explain the observed differ-
ence in significantly elevated liver enzyme values between
clinical trials and non-interventional studies might be due
to fundamental differences between these two types of
studies. For example, clinical studies more intensively and
systematically monitor adverse drug reactions as part of
standard practice, whereas non-interventional studiesgenerally rely more on spontaneous reports of adverse drug
reactions between liver function tests, and may therefore
miss cases of potential liver injury, as abnormal values tend
to normalize within a few weeks [8]. At any rate, one could
argue that findings from non-interventional studies provide
data that is more representative of the general population
than findings from clinical trials, as the inclusion criteria
that participants have to meet in non-interventional studies
tend to be less stringent than those of clinical trials.
Furthermore, findings from Gahr et al. [20] and
Montastruc et al. [48] of pharmacovigilance databases
help to contextualize the risk of agomelatine-induced
liver injury in terms of reported frequency. At the time
of their query, Gahr et al. [20] found that 10% of all sub-
mitted reports of agomelatine-related liver injury to the
selected pharmacovigilance database were of signifi-
cantly elevated liver enzyme values, whereas Montastruc
et al. [48] found agomelatine to account for 10.3% of all
cases of liver injury submitted to the selected pharma-
covigilance databases they reviewed.
These are considerable amounts, but as mentioned by
Gahr et al. [20], such findings cannot be interpreted
as an estimation of the overall incidence rate of
agomelatine-induced liver injury, as physicians are not
required by law to report possible cases of adverse drug
events to the responsible pharmacovigilance database
they surveyed. It is not clear whether this is also the case
in the study by Montastruc and colleagues [48]. How-
ever, Gahr et al. [20] interestingly mention that there is a
trend of underreporting adverse drug events to phar-
macovigilance institutions (see [54]). In any case, such
data are helpful in identifying potential risk factors as-
sociated with agomelatine and liver injury, and here
Gahr et al. [20] highlight the female gender, increased
aged, and polypharmacy. Interestingly, two of these
potential risk factors (i.e., female gender and increased age)
figure in the one published case report of agomelatine-
induced hepatotoxicity found during the writing of this
article [47].
Limitations and strengths
A main limitation of this review is related to publication
bias. It is clear that case reports and studies of pharmacov-
igilance database reviews are inherently biased vis-à-vis
the publication of more severe cases, and as mentioned
previously, cannot be used as an estimate of incidence
rates. Moreover, publication bias is also inherently present
toward the publication of clinical trials where agomelatine
has been found to be more effective and safer than pla-
cebo and/or other ADs. The inclusion of unpublished clin-
ical trials therefore attempted to reduce this bias. A
second limitation regards the inclusion of studies in which
blood samples rather than specific tests of liver function
being stated as part of the study’s safety procedure.
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potential drug-induced liver injury [7], healthcare profes-
sionals prescribing agomelatine must routinely monitor
patients’ liver function, and thus it seems unlikely that any
case of significantly elevated liver enzyme values would
not be reported. Furthermore, this review offers a qualita-
tive summary of agomelatine-induced liver injury. A quan-
titative understanding of this relationship would benefit
the current literature. However, because of the heterogen-
eity between studies, namely in patient inclusion criteria
and study design, combining study results would prove to
be a challenge and would likely lead to the exclusion of
several studies included in this review. Likewise, a quan-
titative comparative assessment of agomelatine-induced
liver injury compared to other commonly prescribed
ADs (i.e., not limited to the four active comparator
ADs used in the clinical trials for agomelatine) was be-
yond the scope of this review, and warrants further
investigation.
The main strength of this review lies in the extensive
inclusion and analysis of both published and unpub-
lished clinical trials, non-interventional studies, pharma-
covigilance database revies and case report for which
agomelatine has been tested in diseases and conditions
not limited to MDD. This allowed to have a broad over-
view of agomelatine-induced liver injury.
Risk-benefit assessment
Given the considerable amount of AD treatments cur-
rently available, and the substantial heterogeneity in pa-
tient response to ADs, there is still a fundamental need
to develop more efficient and especially better tolerated
ADs. As mentioned in the assessment report for agome-
latine by the Committee for Medicinal Products for
Human Use [8], an effective AD with a more favourable
safety profile compared to existing ADs—whether or not
it is found to be more effective than these ADs—would
still be considered a valuable addition to the current AD
treatment armamentarium. This is especially relevant
when one considers that poor compliance due to adverse
drug reactions still remains one of the most common
reasons for treatment discontinuation [22]. In this re-
gard, agomelatine can be judged as a beneficial AD
treatment. Specifically, its unique non-monoaminergic
mechanism of action endows it with a different safety
profile than other existing AD classes. Indeed, compared
to other existing ADs, studies have shown that agomela-
tine poses a low risk of sexual dysfunction, low incidence
of gastrointestinal reactions, lack of significant weight
gain or serotonin syndrome, lack of discontinuation
symptoms, and overall incidence rates of adverse events
similar to those from placebo [8]. These characteristics
are likely to be welcomed by patients, their families, and
healthcare professionals.In terms of liver injury, we have seen that ADs in gen-
eral, including agomelatine, have the potential to cause
liver damage. In this regard, the manufacturer of agome-
latine proposes a detailed liver monitoring program, and
upholds that the benefits of taking agomelatine outweigh
its potential risk of hepatotoxicity if healthcare profes-
sional adhere to it. Interestingly, it has recently been
argued that introducing amendments to the current
threshold values for abnormal ALT and ALP tiers could
provide more specific markers of drug-induced liver in-
jury. For example, Verma and Kaplowitz [55] mention
that the current threshold values (i.e., >3X ULN for ALT
tiers and >2X ULN for ALP tiers) are sensitive, but not
specific markers of liver injury. Thus, at least when con-
sidering ALT values, a new threshold value of 5XULN
has been proposed to limit the withdrawal of drugs in-
correctly identified as being hepatotoxic [56].
Lastly, it is worth mentioning that the metabolic pro-
cesses of the liver, including drug metabolism, are af-
fected by circadian rhythmicity [57]. As agomelatine is
prescribed to be taken in the evening (ref ), whereas
many other ADs are to be taken during the day, consid-
ering the time of day at which ADs are taken and the
resulting effects this has on drug metabolism and poten-
tial liver injury is a factor that warrants closer examin-
ation when comparing agomelatine to other ADs.
Conclusions
Agomelatine prescription at therapeutic doses does pose a
risk of inducing liver injury, which is usually reversible.
However, rare cases of severe and life-threatening hepato-
toxicity have also occurred. Therefore, it is essential that
clinicians continue to monitor liver function frequently, as
prescribed by the manufacturer of agomelatine. Early de-
tection, followed by best practice treatment plan reactions
(e.g., treatment discontinuation), remain the most efficient
responses toward possible manifestations of liver damage.
Informing patients that agomelatine can be associated
with liver injury, that certain factors may increase one’s
risk (e.g., concurrent alcohol use), and that various bio-
logical and clinical manifestations (e.g., fatigue, nausea,
vomiting, dark urine, etc.) may indicate liver injury is of
crucial importance.
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